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INTRODUCTION
Cystic fibrosis (CF) is the most common life-lim-
iting autosomal recessive condition in Caucasians. 
It is caused by a mutation in the gene encoding the 
cystic fibrosis transmembrane conductance regula-
tor (CFTR) protein. The CFTR protein is a chloride 
channel expressed in the apical membrane of epi-
thelial cells. It primarily regulates the movement of 
chloride, but is also involved in sodium, bicarbon-
ate and water transport. Mutations in both copies of 
the gene result in clinical disease (1). Dysfunction of 
CFTR leads to the accumulation of mucus in all tu-
bular structures. Narrowing and obstruction of their 
lumen damages the relevant organs and maintains a 
process of chronic infection (2).
Cystic fibrosis is a complex multisystem disorder 
with a wide and variable spectrum of manifestations. 
The phenotypic alterations are primarily identified 
in the epithelial cells of airways, sinuses, the gastro-
intestinal tract (including the pancreas and biliary 
system), the sweat glands, and the genitourinary sys-
tem (3).
Genetic Knowledge
A great progress in the genetic knowledge of cys-
tic fibrosis was made in the late 20th century. In 
1985, CFTR was mapped. It belongs to the group of 
ATP-binding cassette (ABC) proteins. CFTR follows 
the same domain structure as other ABC transport-
ers: it has two nucleotide-binding domains (NBDs) in 
tandem with two transmembrane domains (TMDs). 
What differentiates it from the other transporters 
(apart from its channel activity) is its regulatory do-
main or ‘R’ region (4). Each TMD is by 6 transmem-
brane helices (TM1–TM6 and TM7–TM12). Every 
membrane spanning domain followed by a nucleo-
tide binding domain (NBD). A distinctive character-
istic of CFTR is the presence of an intrinsically dis-
ordered region, the regulatory domain (RD), locat-
ed between NBD1 and TMD2. In most ABC-proteins 
the ATPase activity of the NBDs utilize the energy of 
ATP binding and hydrolysis to energize the translo-
cation of various substrates across membranes. Con-
versely, CFTR is a unique case of an ABC-protein 
that forms an ATP-gated ion channel. CFTR is ex-
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CFTR Modulator Therapy for Cystic Fibrosis
The currently available products for CFTR mod-
ulator therapy are Kalydeco (ivacaftor) approved in 
2012, Orkambi (ivacaftor / lumikaftor) approved in 
2015, Symdeco / Symkevi (ivacaftor / tezakaftor) ap-
proved in 2018 and Trikafta (elexacaftor / tezacaftor 
/ ivacaftor) approved in 2019.The four listed products 
are from the company Vertex.
They modulate CFTR by acting as potentiators 
(increasing the time during which the CFTR channel 
is open, which leads to greater movement of ions) or 
correctors (facilitating the maturation of CFTR-pro-
tein, which leads to its improved transport to the cell 
membrane) (9). 
Ivacaftor (Kalydeco)
Ivacaftor was approved for the treatment of CF in 
patients ≥2 years of age and the presence of one of the 
following CFTR mutations G551D, G1244E, G1349D, 
G178R, G551S, S1251N, S1255P, S549N, S549R or 
R117H. The use of potentiator ivacaftor resulted in 
significant improvement in percent predicted FEV1 
(10-15%), BMI, sweat chlorine and is generally well 
tolerated. The dosage is 2x150 mg (2x1 tablet every 12 
hours) for patients over 6 years, 2x50 mg (2x1 sachet) 
for patients under 6 years and under 14 kg and 2x75 
mg (2x1 sachet) for patients under 6 years and over 
14 kg. From the summer of 2017 the FDA in the USA 
expands the readings with new mutations of 4th and 
5th class: 2789 + 5G-> A, 3849 + 10kbC-> T, 3272-
26A-> G, 711 + 3A-> G, E56K, P67L, R74W, D110E, 
D110H, R117C, L206W, R347H, R352Q, A455E, 
D579G, E831X, S945L, S977F, F1052V, R1070W, 
F1074L, D1152H and D1270N. Тhe possibility of de-
veloping cataract has been reported as a serious side 
effect (9,10,11).
Orkambi (Ivacaftor / Lumikaftor)
Ivacaftor / lumikaftor is used for patients homo-
zygous for delF508 - class 2 mutation.
It is a combination of ivacaftor with the corrector 
lumacaftor. The use of ivacaftor/lumikaftor resulted 
in a less extent improvement (compared to ivacaftor) 
in FEV1 and sweat test values, but there is proven re-
ductions in exacerbations and improvement in body 
mass index indicators. The dosage is 2x1 tablet, with 
two types of tablets available - lumacaftor 100 mg / 
ivacaftor 125 mg for children 6 to 11 years of age and 
lumacaftor 200 mg / ivacaftor 125 mg for patients 
over 12 years of age. Heaviness in the chest and met-
rorrhagia have been reported as serious side effects 
(9,12).
Symdeco/Symkevi (Ivacaftor/Tezakaftor)
Ivacaftor/tezakaftor is used for heterozygous pa-
tients with delF508 and another mutation of the fol-
lowing: P67L, R117C, L206W, R352Q, A455E, D579G, 
pressed in a variety of organs and tissues including 
gut smooth muscle, tubular kidney cells and muco-
sal and secretory epithelia (5).
CFTR Mutation Classes
There are currently  2088  mutations listed in 
CFTR mutation database (6). These mutations can 
be grouped according to their functional defect into 
seven classes.
Class I mutations affect protein production and 
include mostly nonsense mutations (i.e., those with 
premature stop codons), thus often causing degrada-
tion of mRNA by nonsense-mediated decay. G542X, 
W1282X are examples of mutations causing the 
defect.
Class II mutations include Phe508del and affect 
CFTR protein traffic as a result of protein misfolding 
and retention at the endoplasmic reticulum (ER) by 
the ER quality control mechanism. Such retention is 
followed by premature degradation, which prevents 
the protein from trafficking to the cell surface, thus 
severely reducing CFTR function. F508del, N1303K, 
S945L, H949Y, D979A are examples of mutations 
causing the defect.
Class III mutations impair gating of the CFTR 
channel. G551D is examples of mutation causing the 
defect.
Class IV mutations cause a substantial decrease 
in CFTR channel conductance (i.e., flow) of chlo-
ride and bicarbonate ions. R117H, G622D, M1137V, 
I1139V, D1152H, D1154G, R347P
are examples of mutations causing the defect.
Class V mutations lead to a major reduction in 
the levels of normal CFTR protein, often
because of alternative splicing that generates both 
aberrant and normal mRNA species, the proportion 
between which might vary among patients and in 
different organs of each patient. A455E, D565G are 
examples of mutations causing the defect.
Class VI mutations destabilise CFTR at the cell 
surface, either by increasing CFTR endocytosis or 
by decreasing its recycling back to the cell surface. 
Q1412X, 432delTC, 4279insA are examples of muta-
tions causing the defect.
Class VII mutations have the same outcome as 
class I mutations – i.e., absence of the CFTR pro-
tein—but cannot be rescued by corrective therapy 
(7,8).
The detection of genetic defects in patients with 
cystic fibrosis makes it possible to develop increas-
ingly effective treatment approaches focusing on the 
main classes of mutations, looking for ways to cor-
rect or circumvent the problem in an alternative way.
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711 + 3A-> G, S945L, S977F, R1070W, D1152H, 2789 + 
5G-> A, 3272-26A-> Gi 3849 + 10kbC-> T. It is a com-
bination of Ivacaftor with the corrector tezacaftor. It 
shows better results than Orkambi. The dosage is 1 
tablet Symkevi® in the morning (tezacaftor 100 mg / 
ivacaftor 150 mg) and 1 tablet Kalydeko® in the eve-
ning (ivacaftor 150 mg). No serious side effects have 
been reported 9,13).
Тrikafta (Elexacaftor/Tezacaftor/Ivacaftor)
In 2019 FDA approved Trikafta  (elexacaftor/
tezacaftor/ivacaftor and ivacaftor) to treat the un-
derlying cause of cystic fibrosis in people ages 12 
and older who have at least one F508del mutation. It 
is a combination of Ivacaftor and the correctors el-
exacaftor and tezacaftor. In NEJM Middleton et al. 
published the results of 3-phase, randomized, dou-
ble-blind, and placebo-controlled study of 403 pa-
tients showing the effectiveness of Trikafta. The dos-
age is two elexacaftor 100 mg, tezacaftor 50 mg, and 
ivacaftor 75 mg tablets in the morning and one iva-
caftor 150 mg tablet in the evening. Liver damage 
and cataract have been reported as serious side ef-
fects (14).
CONCLUSION
CFTR modulator therapy significantly improves 
the prognosis and quality of life of cystic fibrosis pa-
tients as a result of certain mutations in the CFTR 
gene. Quality care for other patients with other mu-
tations is especially important so that they can bene-
fit from personalized treatment in the future.
In Bulgaria, the drugs that are reimbursed at 100% 
of the national health insurance fund are Kreon, Pul-
mozyme (dormase alfa), Colobreathe (Colistin) and 
Tobi (Tobramycin). They are given free of charge to 
any patient with a genetically proven cystic fibro-
sis, but there are certain indication for their use. For 
now, the CFTR modulator therapy is difficult to ac-
cess and very expensive for patients in our country, 
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